Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

NCT06340568 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06340568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Recruiting
Start date
June 10, 2025
Completion date
November 30, 2029
Enrollment
480 (estimated)
Sites
191

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer